Concerns Over Liver Toxicity Impacting Intellia (NTLA)

3 months ago

"Intellia down as we've discussed on liver toxicity. I think that severe liver toxicity can be very scary because the drug in question is not being given to lots and lots of people. So if it has a one in 100 or one in 200 chance of liver toxicity, that's not good. Severe liver toxicity, not just transient liver toxicity. There aren't too many CRISPR drugs, and all eyes are on making sure that they're doing everything for the first time in a unique way. So, it's definitely worrisome, especially for the rest of their drugs, because it's kind of the same drug over and over again, just with different genes."

A bearish commentary on Intellia (NTLA) highlighting severe liver toxicity risks associated with its CRISPR drug, suggesting that repeated issues across its product line could lead to further stock declines.

Related Stocks